PDCD1 and B-cell chronic lymphocytic leukemia: The programmed cell death protein 1 (PD-1) blocking antibodies pembrolizumab and nivolumab [27] can provide selective efficacy for CLL patients with Richter’s transformation (RT), an aggressive complication of CLL [28].